Approach to Weakness in Myositis and Myopathy

Dr Neeraj Manikath ,Claude,ai

Here's a comprehensive step-by-step approach to evaluate, diagnose, and manage weakness due to myositis or myopathy:

Step 1: Initial Clinical Assessment

Detailed history taking:
- Pattern of weakness (proximal vs. distal, symmetric vs. asymmetric)
- Tempo of onset (acute, subacute, chronic)
- Associated symptoms (pain, rash, dysphagia, dyspnea)
- Medication history (statins, steroids, immunosuppressants)
- Family history of neuromuscular disorders
- Exposure history (toxins, alcohol, occupational)
Physical examination:
- Manual muscle testing (MMT) using MRC grading scale
- Assessment for muscle tenderness
- Evaluation of deep tendon reflexes
- Skin examination for rashes (heliotrope rash, Gottron's papules)
- Joint examination for arthritis
- Cardiopulmonary assessment

Muscle enzyme panels:
- Creatine kinase (CK) - often markedly elevated
- Aldolase
- Lactate dehydrogenase (LDH)
- Aspartate aminotransferase (AST)
- Alanine aminotransferase (ALT)
Inflammatory markers:
- Erythrocyte sedimentation rate (ESR)
- C-reactive protein (CRP)
Autoimmune serologies:
- Myositis-specific antibodies (MSAs):
  - Anti-Jo-1, anti-SRP, anti-Mi-2, anti-MDA5, anti-TIF1-γ, anti-NXP2
- Myositis-associated antibodies (MAAs):
  - Anti-Ro/SSA, anti-La/SSB, anti-U1-RNP, anti-PM-Scl
Other blood tests:
- Complete blood count
- Comprehensive metabolic panel
- Thyroid function tests
- HMG-CoA reductase antibody (for statin-induced myopathy)
- Vitamin D levels

Electromyography (EMG):
- Assessment for:
  - Spontaneous activity (fibrillations, positive sharp waves)
  - Motor unit potential (MUP) morphology
  - Recruitment pattern
- Typical findings: Increased insertional activity, spontaneous fibrillations, complex repetitive discharges
Nerve conduction studies (NCS):
- To differentiate myopathy from neuropathy

MRI of affected muscles:
- T1-weighted images: assess fatty replacement
- T2-weighted/STIR sequences: evaluate for edema
- Helps identify affected muscles for targeted biopsy
Whole-body MRI:
- For assessment of disease distribution
- Monitoring treatment response

Site selection:
- Moderately affected muscle (not end-stage)
- Preferably guided by MRI findings
Histopathological assessment:
- H&E staining for basic architecture
- Immunohistochemistry for inflammatory cell typing
- Assessment for patterns:
  - Inflammatory myopathies: endomysial, perimysial inflammation
  - Inclusion body myositis: rimmed vacuoles, inclusion bodies
  - Necrotizing myopathy: necrotic fibers with minimal inflammation
  - Metabolic myopathies: specific substrate accumulations

For suspected inflammatory myopathies:
- Chest CT/HRCT (for ILD)
- Malignancy screening (age-appropriate cancer screening)
For suspected metabolic myopathies:
- Forearm ischemic exercise test
- Genetic testing panels
- Mitochondrial studies
- Biochemical enzyme assays
Swallowing assessment:
- Video fluoroscopic swallow study
- Fiberoptic endoscopic evaluation of swallowing (FEES)

Inflammatory myopathies:
- Dermatomyositis (DM)
- Polymyositis (PM)
- Immune-mediated necrotizing myopathy (IMNM)
- Inclusion body myositis (IBM)
- Anti-synthetase syndrome
Non-inflammatory myopathies:
- Metabolic myopathies
- Toxic myopathies
- Endocrine myopathies
- Muscular dystrophies
- Congenital myopathies

For inflammatory myopathies:
- First-line: Corticosteroids (prednisone 0.5-1mg/kg/day)
- Second-line immunosuppressants:
  - Methotrexate (15-25mg/week)
  - Azathioprine (2-3mg/kg/day)
  - Mycophenolate mofetil (2-3g/day)
- Third-line therapies:
  - IVIG (2g/kg divided over 2-5 days)
  - Rituximab (1g x 2 doses, 2 weeks apart)
  - Cyclosporine, tacrolimus, cyclophosphamide
- Newer biologics:
  - JAK inhibitors
  - Anti-type I interferon therapies
For IBM:
- Physical therapy (resistance training)
- Symptomatic management
- IVIG (limited evidence)
- Clinical trials
For metabolic/toxic myopathies:
- Remove offending agent
- Supportive care
- Specific metabolic treatments
Supportive management for all types:
- Physical therapy
- Occupational therapy
- Speech therapy (for dysphagia)
- Respiratory support if needed
- Nutritional support

Clinical assessments:
- Manual muscle testing
- Functional assessments (timed up and go, 6-minute walk test)
- Patient-reported outcome measures
Laboratory monitoring:
- Muscle enzymes (CK, aldolase)
- Inflammatory markers
Repeat imaging:
- MRI to assess disease activity
- Chest imaging for ILD

Dysphagia management:
- Dietary modifications
- Swallowing therapy
Cardiovascular complications:
- ECG monitoring
- Echocardiography
- Treatment of myocarditis
Pulmonary complications:
- Pulmonary function tests
- Management of ILD
- Ventilatory support if needed
Malignancy surveillance:
- Age-appropriate cancer screening
- Additional targeted evaluation based on risk factors

Lundberg IE, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies. Ann Rheum Dis. 2017;76(12):1955-1964.
Schmidt J. Current Classification and Management of Inflammatory Myopathies. J Neuromuscul Dis. 2018;5(2):109-129.
Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7(6):343-354.
Allenbach Y, et al. 2018 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2018;77(12):1-10.
Selva-O'Callaghan A, et al. The diagnostic workup of patients with inflammatory myopathy. Autoimmun Rev. 2020;19(4):102455.
Day J, Patel S, Limaye V. The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46(5):642-649.
Mandel DE, et al. American College of Rheumatology/European League Against Rheumatism classification criteria for adult and juvenile idiopathic inflammatory myopathies. Arthritis Rheumatol. 2017;69(12):2271-2282.
Miller FW, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology. 2001;40(11):1262-1273.